Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘KRAS and VISTA – Better Approaches for Key Targets’ at Canaccord Genuity’s Horizons in Oncology Virtual Conference on Monday, April 15th at 2:00 p.m. ET. Read full article

NEW YORK, March 6, 2024 /PRNewswire/ — OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced that the first patient has been dosed in the Phase 1 study evaluating CUSP06 for the treatment of platinum-refractory/resistant ovarian cancer and other advanced solid tumors. Read full article

Indapta Therapeutics has received FDA Fast Track Designation for its natural killer (NK) cell therapy IDP-023 for patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). The company’s universal, allogeneic NK cell therapy platform is comprised of a potent subset of naturally occurring NK cells called G minus NK (g-NK) cells. Read full article

Indapta Therapeutics has commenced the Phase I clinical trial of natural killer (NK) cell therapy IDP-023, treating the first patients with multiple myeloma and non-Hodgkin’s lymphoma. Read full article

A phase 1 trial recently kicked off evaluating the novel drug, IDP-023 for the treatment of patients with relapsed or refractory multiple myeloma and non-Hodgkin lymphoma, according to a news release issued by Indapta Therapeutics, the manufacturer of the drug. Read the full article

Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced the activation of four clinical trial sites in the United States. These U.S. clinical trial sites in Texas and Virginia are now open and actively enrolling patients. …

In oncology clinical trials, many patients spend their final months at a central clinical trial facility far from home for “mandatory” protocol visits/diagnostic testing. Studies suggest that the travel strain may be greatest among patients living in low‐income areas and/or participating in early-phase studies. In this regard, rare cancers constitute a special unmet need with limited therapeutic options and few …

Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the Group has completed all dosing regimens for its Phase I study of STP707 for the treatment of multiple solid tumors in patients with various types of late-stage cancers who did not …

MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), today announced the successful initiation of patient dosing in its Phase 1/1b study evaluating MBRC-101 in patients with advanced metastatic solid tumors refractory to standard treatment. Read more at MBrace Therapeutics

BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported initial data from the monotherapy dose-escalation portion of its Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor …